• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Crinetics Pharmaceuticals Inc.

    2/27/25 4:23:29 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRNX alert in real time by email
    S-8 1 crnx-20250227.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on February 27, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT UNDER

    THE SECURITIES ACT OF 1933

    CRINETICS PHARMACEUTICALS, INC.

    (Exact Name of Registrant as Specified in its Charter)

    Delaware

    26-3744114

    (State or Other Jurisdiction

    (I.R.S. Employer Identification No.)

    of Incorporation or Organization)

    6055 Lusk Boulevard

    San Diego, California 92121

    (Address of principal executive offices) (Zip code)

    Crinetics Pharmaceuticals, Inc. 2018 Incentive Award Plan

    Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan

    Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan

    (Full title of the plans)

    R. Scott Struthers

    President and Chief Executive Officer

    Crinetics Pharmaceuticals, Inc.

    6055 Lusk Boulevard

    San Diego, California 92121

    (885) 450-6464

    (Name, address, and telephone number, including area code, of agent for service)

    Copies to:

    James Krenn, Esq.
    Morrison & Foerster LLP
    12531 High Bluff Drive
    San Diego, CA 92130
    (858) 720-5100

    G. Scott Lesmes, Esq.

    Emily K. Beers, Esq.

    Morrison & Foerster LLP

    2100 L Street NW, Suite 900

    Washington, D.C. 20037

    (202) 887-1500

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

    Large accelerated filer ý

    Accelerated filer ¨

    Non-accelerated filer ¨

    Smaller reporting company ¨

    Emerging growth company ¨

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

    Proposed sales to take place as soon after the effective date of the Registration Statement as awards granted under the above-named plans are granted, exercised and/or distributed.

     


     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed for the purpose of registering an aggregate of 7,575,584 additional shares of common stock of Crinetics Pharmaceuticals, Inc. (the “Registrant”) issuable or which may become issuable pursuant to awards that may be granted under the Crinetics Pharmaceuticals, Inc. 2018 Incentive Award Plan (the “2018 Plan”) and the Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan (the “2018 ESPP”), in each case, pursuant to the evergreen provisions of such plans, and the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “Inducement Plan”).

    Pursuant to General Instruction E of Form S-8, the contents of the prior registration statements on Form S-8, File No. 333-226234, File No. 333-254883, File No. 333-264005, File No. 333-268328, File No. 333-270125, File No. 333-275366, and File No. 333-277484 previously filed with respect to the 2018 Plan, the 2018 ESPP and the Inducement Plan, are incorporated into this Registration Statement by reference to the extent not modified or superseded hereby or by any subsequently filed document, which is incorporated by reference herein or therein.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    In this Registration Statement, Crinetics Pharmaceuticals, Inc. is sometimes referred to as “Registrant,” “we,” “us” or “our.”

    Item 3. Incorporation of Documents by Reference

    The Securities and Exchange Commission (“SEC”) allows us to “incorporate by reference” the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this Registration Statement, and later information filed with the SEC will update and supersede this information. We hereby incorporate by reference into this Registration Statement the following documents previously filed with the SEC:

    (a)
    The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 27, 2025;
    (b)
    The Registrant’s Current Reports on Form 8-K filed with the SEC on January 10, 2025 and February 24, 2025; and
    (c)
    The description of the Registrant’s common stock set forth in the Registrant’s registration statement on Form 8-A12B (Registration No. 001-38583), filed by the Registrant with the SEC under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on July 12, 2018, including any amendments or reports filed for the purpose of updating such description.

    In addition, all documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which de-registers all securities then remaining unsold shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such statements as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement contained herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

    We are not, however, incorporating by reference any documents or portions thereof, whether specifically listed below or filed in the future, that are not deemed “filed” with the SEC. Under no circumstances shall any information furnished under Item 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

     


     

    Item 8. Exhibits

    Incorporated by Reference

    Exhibit

    Number

    Description

    Form

    Exhibit

    Date Filed

    File Number

    Filed

    Herewith

    3.1

    Amended and Restated Certificate of Incorporation

    8-K

    3.1

    7/20/2018

    001-38583

    3.2

    Amended and Restated Bylaws

    8-K

    3.1

    12/12/2023

    001-38583

    4.1

    Specimen stock certificate evidencing the shares of common stock

    S-1/A

    4.1

    7/9/2018

    333-225824

    5.1

    Opinion of Morrison & Foerster LLP

    X

    10.1

    Crinetics Pharmaceuticals, Inc. 2018 Incentive Award Plan

    S-1/A

    10.3

    7/9/2018

    333-225824

    10.2

    Form of Stock Option Agreement under Crinetics Pharmaceuticals, Inc. 2018 Incentive Award Plan

     S-1/A

     10.4

    7/9/2018

     333-225824

     

    10.3

    Form of Restricted Stock Unit Agreement under Crinetics Pharmaceuticals, Inc. 2018 Incentive Award Plan

    10-K

    10.5

    3/30/2022

    001-38583

    10.4

     

    Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan and offering document thereunder

     

    S-1/A

     

    10.5

     

    7/9/2018

    333-225824

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    10.5

    Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan and Form of Stock Option Agreement thereunder

    8-K

     

    10.1

     

    12/23/2021

     001-38583

    10.6

    Amendment to the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan

     

     10-Q

     

     10.3

     

     11/14/2022

     001-38583

     

    10.7

    Amendment No. 2 to the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan

     

    10-K

     

    10.19

     

    2/28/2023

    001-38583

    10.8

     

    Amendment No. 3 to the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan

    10-Q

    10.1

    11/7/2023

    001-38583

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    10.9

     

    Amendment No. 4 to the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan

     

    10-K

     

    10.19

     

    2/27/2025

    001-38583

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.1

    Consent of Morrison & Foerster LLP (included in Exhibit 5.1)

    X

    23.2

    Consent of BDO USA, P.C., independent registered public accounting firm

    X

    24.1

    Power of Attorney (included in the signature page to this Registration Statement)

    X

    107

    Filing Fee Table

    X

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on February 27, 2025.

    CRINETICS PHARMACEUTICALS, INC.

    By:

    /s/ R. Scott Struthers, Ph.D.

    Name:

    R. Scott Struthers, Ph.D.

    Title:

    President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints R. Scott Struthers, Ph.D. and Marc J.S. Wilson, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

    Name

    Title

    Date

    /s/ R. Scott Struthers, Ph.D.

    President, Chief Executive Officer and Director

    February 27, 2025

    R. Scott Struthers, Ph.D.

     (principal executive officer)

    /s/ Marc J.S. Wilson

    Chief Financial Officer

    February 27, 2025

    Marc J.S. Wilson

     (principal financial and accounting officer)

    /s/ Wendell Wierenga, Ph.D.

     Chairman of the Board of Directors

    February 27, 2025

    Wendell Wierenga, Ph.D.

    /s/ Camille Bedrosian, M.D.

     Director

    February 27, 2025

    Camille Bedrosian, M.D.

    /s/ Caren Deardorf

     Director

    February 27, 2025

    Caren Deardorf

    /s/ Matthew K. Fust

     Director

    February 27, 2025

    Matthew K. Fust

    /s/ Weston Nichols, Ph.D.

     Director

    February 27, 2025

    Weston Nichols, Ph.D.

    /s/ Stephanie Okey

     Director

    February 27, 2025

    Stephanie Okey

    /s/ Rogério Vivaldi Coelho, M.D.

    Director

    February 27, 2025

    Rogério Vivaldi Coelho, M.D.


     

     


    Get the next $CRNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRNX

    DatePrice TargetRatingAnalyst
    1/12/2026$67.00Neutral → Buy
    Goldman
    7/10/2025$36.00Neutral
    Goldman
    3/25/2025$60.00Buy
    Stifel
    2/11/2025Buy
    TD Cowen
    2/4/2025Peer Perform
    Wolfe Research
    1/22/2025$55.00Hold → Buy
    Jefferies
    3/6/2024$68.00Buy
    Citigroup
    1/16/2024$50.00Overweight
    Morgan Stanley
    More analyst ratings

    $CRNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Kalofonos Isabel exercised 2,500 shares at a strike of $40.59 and sold $137,500 worth of shares (2,500 units at $55.00) (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    1/7/26 5:11:26 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Betz Stephen F. exercised 18,000 shares at a strike of $1.91, increasing direct ownership by 18% to 117,713 units (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    12/29/25 4:36:41 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Struthers Richard Scott exercised 44,742 shares at a strike of $13.09, increasing direct ownership by 14% to 364,759 units (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    12/18/25 6:54:46 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Crinetics Pharmaceuticals Inc.

    SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    2/5/26 2:45:45 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

    1/26/26 9:06:54 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Crinetics Pharmaceuticals Inc.

    8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

    1/13/26 5:02:11 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March

    SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that company management will participate in the following two upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston, MA Fireside chat on Wednesday, March 4, 2026 at 1:50 p.m. Eastern TimeWebcast link HERE Management will be available for 1x1 meetings with investors on Wednesday, March 4, 2026 Leerink Annual Global Healthcare Conference, Miami, FL Management will be available for 1x1 meetings with investors on Wednesday, March 11, 2026 The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the C

    2/5/26 4:05:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 26 at 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 646-844-6383Access Code: 027322    Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection,

    1/26/26 5:00:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

    SAN DIEGO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate for the proposed treatment of classic congenital adrenal hyperplasia (CAH) in children and adolescents. "BALANCE-CAH is designed to evaluate atumelnant for the treatment of CAH in pediatric age patients – for whom the lifelong burden of this disease begins early," said Dr. Alan Krasner, M.D., Chief Endocrinologist, Crinetics. "For children living with CAH, correcting elevated

    1/22/26 4:05:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Crinetics Pharmaceuticals upgraded by Goldman with a new price target

    Goldman upgraded Crinetics Pharmaceuticals from Neutral to Buy and set a new price target of $67.00

    1/12/26 7:47:46 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Crinetics Pharmaceuticals with a new price target

    Goldman initiated coverage of Crinetics Pharmaceuticals with a rating of Neutral and set a new price target of $36.00

    7/10/25 8:53:33 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Crinetics Pharmaceuticals with a new price target

    Stifel initiated coverage of Crinetics Pharmaceuticals with a rating of Buy and set a new price target of $60.00

    3/25/25 8:26:55 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Leadership Updates

    Live Leadership Updates

    View All

    Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

    SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Tobin "Toby" Schilke as chief financial officer, effective February 28, 2025. Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience. In prior roles, his leadership was instrumental in transforming several biotech companies from R&D-focused entities into fully integrated commercial organizations. "I am excited to welcome Toby to our senior leadership team during this transformational stage of our evolution into a global pharmaceutical company," said Scott Struthers, Ph.D., founder and chief executive officer of Crineti

    2/24/25 8:30:00 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

    SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will lead the company's commercial strategy and operations for the potential launch of paltusotine, the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist for adults living with acromegaly and will lead pre-commercialization activities for the company's deep, innovative pipeline of candidates. "Isabel is a highly accomplished leader with broad commercial expertise ranging from launching therapies to leading early-stage commercial strategy," said Scott Struthers, Ph.D

    12/16/24 8:00:00 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs

    SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board-certified physician in endocrinology, diabetes and metabolism with more than 30 years of experience spanning clinical practice and pharmaceutical industry medical affairs. "Dr. Cuddihy's wealth of knowledge and experience both as a practicing physician in endocrinology and working within the pharmaceutical industry is an invaluable addition to our talented scientific leadership team," said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "As we forg

    5/30/24 4:05:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

    SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 7:55:29 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

    SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 5:46:54 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Crinetics Pharmaceuticals Inc.

    SC 13G - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 1:22:38 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Financials

    Live finance-specific insights

    View All

    Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 26 at 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 646-844-6383Access Code: 027322    Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection,

    1/26/26 5:00:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

    Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (80 mg) Achieved a 67% Mean Reduction in Androstenedione Levels While Simultaneously Enabling 88% of Participants Completing 12 Weeks of Treatment to Successfully Reduce Glucocorticoid Dose to Physiologic Replacement Levels Atumelnant's Favorable Benefit/Risk Profile Was Maintained in Cohort 4 and Open-Label Extension of Phase 2 CAH Study With No Hepatic Transaminase Adverse Events Management to Host Investor Conference Call Today at 8:30 AM ET SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cr

    1/5/26 8:00:00 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

    SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide an update on PALSONIFY™ (paltusotine) commercialization and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia. Conference Call and Webcast DetailsManagement will hold a live conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET. A live question-and-answer session will follow the prepared remarks. To access the live audio-only webcast, click here. The archived webcast will also be accessible

    1/4/26 4:00:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care